Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, have proven effective in resisting obesity and improving hyperglycemia, insulin sensitivity, and blood pressure by inhibiting food intake, as demonstrated in both preclinical and clinical studies. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.